An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Conditions
Urinary Bladder
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.
- Trial withSeattle Genetics, Inc.
- Start Date02/24/2022
- End Date11/30/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Andrea Brennan
- Andrea Martelli
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Hari Deshpande, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Joseph Kim, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Khanh Nguyen, MD
- Kristen Hoxie
- Lynn Cochran
- Madeline Santiago
- Michael Cohenuram, MD
- Michael Hurwitz, PhD, MD
- Neal Fischbach, MD
- Ninani Kombo, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Sarah Carlson
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Victor Chang, MD
- Wajih Kidwai, MD, FACP
- Last Updated06/14/2022
- Study HIC#2000027665